ABN 82 010 975 612
Progen Expands Board of Directors
· Two new independent non-executive directors added to Board with complimentary skill-sets
· Dr Mal Eutick, OAM appointed independent non-executive Chairman
Brisbane, Australia. 4 March 2008: Progen Pharmaceuticals Limited (ASX: PGL; NASDAQ: PGLA) today
announced the appointment of John Lee and Robert Williamson to the Company’s Board as independent non-
executive directors following an extensive search as previously announced, further the Board appoint Dr Mal
Eutick as independent non-executive Chairman. Mr Stephen Chang becomes a non-executive director.
These additions and changes strengthen and focus the Board’s expertise as Progen embarks on its next stage of
growth with the continued development and commercialization of PI-88 and the recently acquired epigenetics
platform (the CellGate acquisition).
A summary of the recent appointees to the Board follow:
· Mr John Lee. Independent non-executive director. Investor relations expert, Australian and US
management and Board experience, including directorships with several other biotech companies.
· Mr Robert Williamson. Independent non-executive director. Considerable US biotechnology
experience in the areas of business, finance and drug development.
Dr Mal Eutick, currently an independent non-executive director becomes Chairman with the stepping down of
Stephen Chang as previously announced. Dr Eutick has e xtensive Board experience in the healthcare industry
and development of pharmaceutical businesses including founding Phebra (formerly Pharmalab), a critical
medicine drug company.
“John Lee’s considerable knowledge of global financial markets will be invaluable to Progen,” said Progen’s
newly appointed Chairman, Dr Mal Eutick. “Over the years, he has developed deep relationships in the financial
and investor community, which will enhance shar